Recent News

Can Postoperative Radiotherapy Improve Survival Outcomes in Patients With NSCLC?

Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

Preliminary Results With Novel EGFR Inhibitor for EGFR-Mutated Lung Cancer

Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer

Breakthrough Therapy Designation Given to Adagrasib for KRAS G12C–Mutated NSCLC

Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?

ASCO 2021: LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer

ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer

AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer

Is KRAS Status Linked to Response to Immunotherapy for Advanced Lung Cancer?

ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer

Robotic Bronchoscopy May Improve Timing and Accuracy of Lung Cancer Diagnosis

ASCO 2021: Video-Assisted Thoracoscopy Versus Open Lobectomy for Early-Stage Lung Cancer

$20 Million Donation to MSK to Support Lung Cancer Research

ASCO 2021: Subgroup Efficacy Analysis of Sotorasib for Advanced KRAS G12C–Mutated NSCLC

ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

Anti–PD-1 Monoclonal Antibody Plus Chemotherapy for Advanced Squamous NSCLC

Sotorasib Receives Approval for NSCLC With KRAS G12C Mutations

FDA Accepts Submission for Sintilimab in Combination With Pemetrexed/Platinum Chemotherapy in NSCLC

Does Performance Status Correlate With Survival in Pembrolizumab-Treated Patients With NSCLC?

FDA Approves Targeted Therapy Amivantamab-vmjw for Subset of NSCLC

ASCO 2021: Atezolizumab in Early-Stage Resected NSCLC After Chemotherapy

RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC

Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC

AACR 2021: Influence of Aneuploidy on Response to Immunotherapy for Lung Cancer

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC

Brigatinib in Alectinib-Resistant ALK-Positive NSCLC

Updated USPSTF Recommendation on Lung Cancer Screening

Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC

Tyrosine Kinase Inhibitor Combination Therapy for HER2-Mutated NSCLC

Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC

Do Tailored Chemotherapy Regimens Improve Outcomes in Early-Stage NSCLC?

FDA Expands Approval of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer

Tyrosine Kinase Inhibitor Therapy for Stage III EGFR-Mutated NSCLC

WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC

WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC

FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC

WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC

Sotorasib Receives FDA Priority Review for KRAS G12C–Mutated Advanced Lung Cancer

WCLC 2020: KEYNOTE-799 Update on Pembrolizumab With Chemoradiotherapy in Stage III Lung Cancer

WCLC 2020: Updated Overall Survival With Atezolizumab in NSCLC From IMpower110

WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC

WCLC 2020: Genomic Analysis of Women With Lung Cancer Who Never Smoked

WCLC 2020: Adding Ipilimumab to Pembrolizumab for Metastatic NSCLC